Overview
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
Eligibility
Inclusion Criteria:
- Is willing and able to complete all study assessments
Exclusion Criteria:
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)
- Has total bilirubin \>ULN
- Has no history of invasive infection by an encapsulated organism
- Has no known complement or immunologic deficiency


